Low Level of Microsatellite Instability Correlates with Poor Clinical Prognosis in Stage II Colorectal Cancer Patients

Ehsan Nazemalhosseini Mojarad,1 Seyed Mohammad Hossein Kashfi,2 Hanieh Mirtalebi,1 Mohammad Yaghoob Taleghani,2 Pedram Azimzadeh,1 Sanaz Savabkar,1 Mohammad Amin Pourhoseingholi,2 Hasan Jalaeikhoo,3 Hamid Asadzadeh Aghdaei,1 Peter J. K. Kuppen,4 and Mohammad Reza Zali2

1Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3A J A Cancer Research Center (ACRC), A J A University of Medical Sciences, Tehran, Iran
4Department of Surgery, Leiden University Medical Center, Leiden, Netherlands

Correspondence should be addressed to Mohammad Reza Zali; nnzali@hotmail.com

Received 30 December 2015; Accepted 19 May 2016

Copyright © 2016 Ehsan Nazemalhosseini Mojarad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The influence of microsatellite instability (MSI) on the prognosis of colorectal cancer (CRC) requires more investigation. We assessed the role of MSI status in survival of individuals diagnosed with primary colorectal cancer. In this retrospective cross-sectional study the MSI status was determined in 158 formalin-fixed paraffin-embedded tumors and their matched normal tissues from patients who underwent curative surgery. Cox proportional hazard modeling was performed to assess the clinical prognostic significance. In this study we found that MSI-H tumors were predominantly located in the colon versus rectum \((p = 0.03)\), associated with poorer differentiation \((p = 0.003)\) and TNM stage II/III of tumors \((p = 0.02)\). In CRC patients with stage II, MSI-L cases showed significantly poorer survival compared with patients who had MSI-H or MSS tumors \((p = 0.04)\). This study indicates that MSI-L tumors correlate with poorer clinical outcome in patients with stage II tumors \((p = 0.04)\) or in tumors located in the colon \((p = 0.02)\). MSI-L characterizes a distinct subgroup of CRC patients who have a poorer outcome. This study suggests that MSI status in CRC, as a clinical prognostic marker, is dependent on other factors, such as tumor stage and location.

1. Introduction

Colorectal cancer (CRC) develops either sporadically (85% of the cases), as part of a hereditary cancer syndrome (≤10%), or as a background of inflammatory bowel disease [1]. The incidence of CRC in Iran has been significantly increased since 1970 [2, 3]. According to Iran National Cancer Registry (INCR) report, approximately 51,000 new cases of cancers with mortality rate of 35,000 are identified every year. This makes cancer the third most common cause of mortality in Iran. In this regard, CRC is considered as the fourth most common cancer in Iranian population [4, 5]. The prevalence however is different in Iranian male and female gender. In this regard, CRC is the fourth most common cancer in Iranian male and the second in female [4, 6–9].

Two distinct pathways have been identified as main players in CRC: the microsatellite instability (MSI) and the chromosomal instability (CIN)/microsatellite stable (MSS) pathway [10]. Findings of these two pathways have led to the paradigm of CRC as a genetically heterogeneous disease. MSI pathway in hereditary and sporadic colorectal cancer occurs through two different mechanisms. In hereditary nonpolyposis colorectal cancer (HNPCC) the cause is a germline mutation in one of the DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2), while MSI in sporadic colorectal
cancer is predominantly due to hypermethylation of the MLH1 promoter and sometimes sporadic mutations [11]. The DNA mismatch repair system works as a spell checker that identifies and then corrects mismatched base pairs in the DNA. Defects in the mismatch repair mechanisms lead to MSI status [1, 11, 12]. Currently, tumor stage is the most important predictor of prognosis for CRC patients. Implications of MSI in colorectal cancer continue to increase and many studies have evaluated the role of MSI test in clinical management [10–12]. Investigation of MSI status in CRC is warranted for three reasons: (a) as a potential screening tool for HNPCC, (b) as a potential predictive factor of chemotherapy response, and finally (c) as a prognostic marker [13]. The prognostic significance of MSI for patients with colorectal cancer is a subject of controversy. The mechanism by which MSI possibly influences clinical outcome is unknown. Based on the number of markers displaying MSI per tumor, three groups of tumors are defined: those with 30–40% of the markers showing instability (MSI-H); those with less than 30–40% of the markers showing instability (MSI-L), and those showing no instability (MSS) [14]. Some investigations reported that patients with MSI-H tumors have a better prognosis than those with MSI-L or MSS tumors [15, 16], whereas others reported that MSI in colorectal cancer was not an independent prognostic factor or had no prognostic significance in colorectal cancer [17, 18]. The biologic defect producing the low MSI (MSI-L) phenotype in colorectal cancer is poorly recognized; since there is no obvious biologic differentiation between MSI-L and microsatellite stable (MSS) colorectal cancer, these two phenotypes are generally merged when analyzed against the well-defined high MSI (MSI-H) phenotype. Recently, there is controversy in the definition of MSI-L because most tumors could be classified as MSI-L if an adequate number of markers are studied [19]. Several studies have demonstrated the prevalence of MSI among CRC patients in Iran [20–23]. However, information about the survival or mortality rate is unknown. In the present study, we evaluated the possible prognostic significance of MSI in colorectal cancer patients by determining the relationship between MSI status (MSI-H, MSI-L, and MSS) and prognosis in 158 patients who underwent resection for primary colorectal cancer.

2. Materials and Methods

In this study 158 consecutive CRC patients referred to Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, from 2004 to 2010. The patients, who underwent surgical resection of adenocarcinoma of the colon or rectum and their characteristic and clinical data were available, were retrospectively included in this study. Informed consent was obtained from all patients or their relatives. Clinical information was recorded prospectively and registered in a database; this information included (i) age, sex, and personal and family medical history and (ii) tumor location, tumor differentiation, and TNM stage. Ethical approval for the study was obtained from the institutional review boards of the relevant centers.

2.1. MSI Analysis. Serial sections (5 μm) from formalin-fixed paraffin-embedded matched normal and tumor tissues were routinely stained, and representative normal and tumor regions were identified by microscopic examination. Genomic DNA from each tumor and from corresponding normal tissue was purified using the QIAamp Tissue Kit (QIAGEN GmbH, Germany). Yield and purity of products were determined by electrophoresis on 0.8% agarose gel and spectrophotometry absorbance at 260 nm. Determination of MSI status was carried out using five mononucleotide repeat microsatellite targets (BAT25, BAT26, NR21, NR24, and NR27) using standard PCR techniques [24]. PCR products were denatured by electrophoresis on 5% denaturing polyacrylamide gels and were analyzed by an ABI 3130xl automated sequencer (Applied Biosystems, USA). Tumor samples that exhibited different allele peaks than the corresponding normal sample(s) were classified as MSI for that particular marker. MSI-H is defined when at least two of the five standard markers show instability in tumor DNA. MSI-L is defined when one MSI marker shows instability and others were microsatellite stable (MSS) when there was no instability detected on tumors. Analysis was performed twice if the results were ambiguous. The TNM (tumor, lymph nodes, and metastasis) staging system was applied to determine the severity of disease and the local or distant extent of disease spread. The TNM staging system of the American Joint Committee on Cancer (AJCC) is the preferred and standard staging system for CRC.

2.2. Statistical Analysis. Since the significance of MSI-L in CRC is poorly understood, phenotype of MSI was originally grouped into three levels including MSI-High, MSI-Low, and MSS-Stable. Analysis was performed twice if the results were ambiguous. Statistical analysis was performed using the SPSS software program for Windows, Release 13.0.0 (SPSS Inc., Chicago, IL). Comparison of variables was performed using Pearson’s Chi-square test, Fisher’s exact test, or the Mann-Whitney U test, depending on the nature of the data. Two-tailed p < 0.05 was considered statistically significant. Colorectal cancer (CRC) overall survival was computed since the date of cancer diagnosis up to the date of death or end of follow-up (February, 2014). Patients who died due to causes which were unrelated to colorectal cancer were censored at the time of death and were excluded from the analyses. For survival analyses, the following variables were assessed: age, sex, location of the tumor (colon versus rectum), tumor-node-metastasis stage, and grade of differentiation (well/moderate versus poor), use of adjuvant therapy, age of diagnosis, family history and MSI. Overall survival analyses were done through a Cox proportional hazard function for both univariate and multivariate analyses and Kaplan-Meier (log-rank test) curves were plotted. Significance for all statistics were recorded if p < 0.05.

3. Results

3.1. Patients Descriptive. We identified 158 consecutive patients with colorectal cancer of whom pathological results and follow-up data were available. The clinicopathological
Table 1: Clinicopathologic characteristics of patients enrolled in this study.

| Variable            | Total (N) |
|---------------------|-----------|
| No patients         | 158       |
| Gender              |           |
| Female              | 82        |
| Male                | 76        |
| Location of tumor   |           |
| Colon               | 92        |
| Rectum              | 66        |
| Differentiation     |           |
| Well                | 64        |
| Moderately          | 51        |
| Poorly              | 39        |
| TNM stage           |           |
| I                   | 21        |
| II                  | 73        |
| III                 | 57        |
| IV                  | 7         |
| MSI status          |           |
| MSI-H               | 35        |
| MSI-L               | 21        |
| MSS                 | 102       |
| Family history      |           |
| No*                 | 88        |
| Yes                 | 70        |
| No FDR with CRC or adenoma | 28 |
| One or more FDR with CRC or adenoma | 17 |
| One or more FDR with CRC or adenoma | 25 |
| Adjuvant therapy    |           |
| Yes                 | 39        |
| No                  | 119       |
| Vital status        |           |
| Alive               | 141       |
| Deceased            | 17        |
| Age of diagnosis    |           |
| <50                 | 89        |
| >50                 | 69        |
| Metastases          |           |
| No                  | 129       |
| Yes                 | 29        |
| Metastases location |           |
| Liver               | 14        |
| Ovary               | 6         |
| Other               | 9         |

* No history of CRC, adenoma, or HNPCC related cancers.

The most unstable marker was NR24 detected in 9 cases followed by Bat 25 (6 case), NR21 (3 case) and Bat26 (3 case). However none of MSI-L tumors were unstable for NR27 mononucleotide marker. Table 2. The clinicopathological characteristic of patients according to MSI status is shown in Table 3. The mean period of follow-up was 60.2±24.5 months and the median period of follow-up were 53 months (range 2–120). Of 158 patients, 70 cases had family history of CRC and 88 did not have any history of CRC or other gastrointestinal cancers. According to our findings 29 patients had metastatic in the time of diagnosis and 129 were negative for metastatic status. Patients in the MSS group were found to be older than patients in the MSI-L and MSI-H groups (mean ages 53.16 years, 49.6 years and 50.32 years resp.). However this was not statistically significant. Interestingly, the high incidence of MSI-H (24/35, 68.6%) were presented in male gender and there was statistically significant relationship between MSI status and gender (p = 0.019). We found that MSI-H colorectal cancer were located predominantly in proximal colon sites versus rectal sites (p = 0.030), associated with poorer differentiation (p = 0.003), have a family history for GI cancer (p < 0.001), and showed less frequent systemic metastasis (p = 0.050) than MSI-L and MSS colorectal cancer. Distribution of tumor stages I–IV differed among patients with MSI-H, MSI-L and MSS tumors (p = 0.028).

Table 2: Frequency of instability in tumors according to pentaplex mononucleotide markers.

| MSI status | Total | BAT-25 | BAT-26 | NR-21 | NR-24 | BAT-27 |
|------------|-------|--------|--------|-------|-------|--------|
| MSI-H      | 35    | 28 (80)| 21 (60)| 12 (34.3)| 33 (91.4)| 7 (20) |
| MSI-L      | 21    | 6 (12.6)| 3 (6.3)| 3 (6.3)| 9 (18.9)| 0      |
| MSS        | 102   | 0      | 0      | 0      | 0      | 0      |

The clinicopathologic characteristic of patients according to MSI status is shown in Table 3. The mean period of follow-up was 60.2±24.5 months and the median period of follow-up were 53 months (range 2–120). Of 158 patients, 70 cases had family history of CRC and 88 did not have any history of CRC or other gastrointestinal cancers. According to our findings 29 patients had metastatic in the time of diagnosis and 129 were negative for metastatic status. Patients in the MSS group were found to be older than patients in the MSI-L and MSI-H groups (mean ages 53.16 years, 49.6 years and 50.32 years resp.). However this was not statistically significant. Interestingly, the high incidence of MSI-H (24/35, 68.6%) were presented in male gender and there was statistically significant relationship between MSI status and gender (p = 0.019). We found that MSI-H colorectal cancer were located predominantly in proximal colon sites versus rectal sites (p = 0.030), associated with poorer differentiation (p = 0.003), have a family history for GI cancer (p < 0.001), and showed less frequent systemic metastasis (p = 0.050) than MSI-L and MSS colorectal cancer. Distribution of tumor stages I–IV differed among patients with MSI-H, MSI-L and MSS tumors (p = 0.028).

3.2. Microsatellite Instability. The subjects were subdivided into three groups by MSI testing: Thirty-five (22.2%) tumors were MSI-H, 21 MSI-L (13.3%) and 102 MSS (64.5%). Among 35 MSI-H tumors, instability of two markers was detected in 15 tumors (42.8%), 12 tumors (34.2%) had instability in three markers and 5 tumors (14.3%) had instability in four markers and 3 tumors (8.6%) were instable in all five mononucleotide markers. NR24 was the most unstable marker (33 tumor) among MSI-H patients, However in 21 MSI-Low patients,
Table 3: Clinicopathological features of the study population according to MSI status.

|                  | Total  | MSI-H | MSI-L | MSS     | p value |
|------------------|--------|-------|-------|---------|---------|
|                  | N      | N (%) | N (%) | N (%)   |         |
| Patients         | 158    | 35 (22.2) | 21 (13.3) | 102 (64.55) |         |
| Mean age         | Years  | 50.32 | 49.6  | 53.16   | 0.155   |
| Gender           |        |       |       |         |         |
| Female           | 82     | 11 (31.4) | 11 (52.4) | 60 (58.8) | 0.019   |
| Male             | 76     | 24 (68.6) | 10 (47.6) | 42 (41.2) |         |
| Location of tumor|        |       |       |         |         |
| Colon            | 92     | 27 (77.1) | 11 (52.4) | 54 (52.9) | 0.030   |
| Rectum           | 66     | 8 (22.9)  | 10 (47.6) | 48 (47.1) |         |
| Differentiation  |        |       |       |         |         |
| Well             | 64     | 8 (22.9)  | 9 (42.9)  | 47 (46.1) | 0.003   |
| Moderately       | 51     | 8 (22.9)  | 7 (33.3)  | 36 (33.3) |         |
| Poorly           | 39     | 19 (54.3) | 5 (23.8)  | 19 (18.6) |         |
| TNM stage        |        |       |       |         |         |
| I                | 21     | 3 (8.6)   | 2 (9.5)   | 16 (15.7) | 0.028   |
| II               | 73     | 11 (31.4) | 10 (47.6) | 52 (51.0) |         |
| III              | 57     | 21 (60.0) | 8 (38.1)  | 28 (27.5) |         |
| IV               | 7      | —       | 1 (4.8)   | 6 (5.9)   |         |
| T stage          | (T1: T2: T3: T4) | 4 (11.4): 2 (5.7): 29 (82.9): — | 1 (4.8): 2 (9.5): 15 (71.4): 3 (14.3): 16 (15.7): II 10 (10.8): 66 (64.7): 9 (8.8) | 0.104   |
| N stage          | (N0: N1: N2) | 14 (40.0): 17 (48.6): 4 (11.4) | 12 (57.1): 7 (33.3): 2 (9.5) | 71 (69.6): 25 (24.5): 6 (5.9) | 0.043   |
| M stage          | (M0: M1) | 35 (100): — | 20 (95.2): 14 (4.8) | 96 (94.1): 6 (5.6) | 0.162   |
| Family history   | Yes    | 70     | 24 (86.8) | 9 (42.9) | 37 (36.3) | <0.0001 |
|                  | No     | 88     | 11 (31.4) | 12 (57.1) | 65 (63.7) |         |
| Adjuvant therapy | Yes    | 39     | 2 (10.5)  | 7 (33.3) | 30 (29.4) | 0.054   |
|                  | No     | 119    | 33 (94.3) | 14 (66.7) | 72 (70.6) |         |
| Vital status     | Living | 141    | 32 (91.4) | 17 (81.0) | 92 (90.2) | 0.463   |
|                  | Deceased | 17   | 3 (8.6)   | 4 (19.0)  | 10 (9.8)  |         |
| Age of diagnosis | <50    | 89     | 14 (40.0) | 15 (71.4) | 60 (58.8) | 0.049   |
|                  | >50    | 69     | 21 (60.0) | 6 (26.6)  | 42 (41.2) |         |
| Metastases       | Yes    | 29     | 2 (5.7)   | 4 (19.0)  | 23 (22.5) | 0.050   |
|                  | No     | 129    | 33 (94.3) | 17 (81.0) | 79 (77.5) |         |

on overall survival in all colorectal cancer patients (p = 0.426). We also obtained Kaplan-Meier curves of overall survival in patients according to MSI status, stratified based on tumor location and TNM stages (Figures 2 and 3). Based on our results, in CRC Patients with stage I, MSI status is not considered as a valuable prognostic markers, Long Rank p = 0.742. Whereas in CRC Patients with stage II, MSI-L showed significantly poorer survival compared with patients who had MSI-H or MSS tumors, Long Rank p = 0.048, (Figure 2(a)). This indicates that MSI-L was clearly a marker of poorer prognosis in stage II colorectal cancers. However, we did not observe any significant association between overall survival of patients in advanced stages III/IV with MSI status, Long Rank p = 0.430, (Figure 2(b)). Kaplan-Meier curves of overall survival in patients according to MSI status stratified based on tumor location including colon and rectum are presented in Figures 3(a) and 3(b) respectively. According to our findings, patients with MS-L colon tumors, show significantly poorer survival compared with patients who had MSI-H or MSS tumors, Long Rank p = 0.028. But we did not observe the similar results in rectal tumors, Long Rank p = 0.180.

4. Discussion

Several epidemiological studies in Iran demonstrated that in comparison to western populations, the incidence of CRC is significantly higher in young Iranian patients and it has been reported that approximately 20% of all CRC cases occur in patients less than 40 years, whereas, this rate is extremely lower in western countries with 2 to 8% [25–30]. In addition to this high distribution of CRC prevalence in younger population of Iran in previous studies, in one study Azadeh et al. even reported a considerably higher proportion of 43% CRC incidence in patients less than 50 years old in Iranian population [27]. Although genetic factors have been proposed as one of the main risk factors contributed to this early onset of CRC in Iran, However, some studies indicated that this might be due to the high proportion of
Table 4: Univariate and multivariate Cox regression analysis of possible prognostic variables and parameters that correlate with overall survival.

|                                | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | Hazard ratio for death (95% confidence interval) | p value | Hazard ratio for death (95% confidence interval) | p value |
| Gender                         |                     |                       |                       |         |
| Female                         | 1 ref.              |                       |                       |         |
| Male                           | 1.659 (0.630–4.368) | 0.305                 | 1.647 (0.524–5.180)   | 0.393   |
| Location of tumor              |                     |                       |                       |         |
| Rectum                         | 1 ref.              |                       |                       |         |
| Colon                          | 1.418 (0.524–3.836) | 0.492                 | 1.555 (0.480–5.031)   | 0.461   |
| Differentiation                |                     |                       |                       |         |
| Well                           | 1 ref.              |                       |                       |         |
| Moderately                     | 0.700 (0.234–2.091) | 0.523                 | 0.756 (0.221–2.587)   | 0.656   |
| Poorly                         | 0.546 (0.147–2.031) | 0.367                 | 0.375 (0.076–1.840)   | 0.227   |
| TNM stage                      |                     |                       |                       |         |
| I                              | 1 ref.              |                       |                       |         |
| II                             | 0.561 (0.103–3.065) | 0.505                 | 0.621 (0.097–3.969)   | 0.614   |
| III                            | 0.758 (0.379–8.142) | 0.471                 | 3.848 (0.612–24.192)  | 0.151   |
| IV                             | 4.277 (0.599–30.522)| 0.147                 | 10.087 (0.803–126.629)| 0.073   |
| Family history                 |                     |                       |                       |         |
| No                             | 1 ref.              |                       |                       |         |
| Yes                            | 0.672 (0.256–1.768) | 0.421                 | 0.746 (0.210–2.655)   | 0.651   |
| Adjuvant therapy               |                     |                       |                       |         |
| No                             | 1 ref.              |                       |                       |         |
| Yes                            | 1.224 (0.430–3.482) | 0.705                 | 0.274 (0.063–1.195)   | 0.085   |
| MSI results                    |                     |                       |                       |         |
| MSS                            | 1 ref.              |                       |                       |         |
| MSI-L                          | 0.915 (0.251–3.336) | 0.893                 | 2.105 (0.584–7.580)   | 0.255   |
| MSH                            | 2.026 (0.635–6.462) | 0.233                 | 0.512 (0.094–2.797)   | 0.440   |
| Metastases                     |                     |                       |                       |         |
| No                             | 1 ref.              |                       |                       |         |
| Yes                            | 0.392 (0.145–1.061) | 0.065                 | 2.799 (0.707–11.084)  | 0.143   |
| Age of diagnosis               |                     |                       |                       |         |
| <50                            | 1 ref.              |                       |                       |         |
| >50                            | 0.723 (0.274–1.907) | 0.512                 | 2.240 (0.546–9.182)   | 0.263   |

Figure 1: Kaplan-Meier curves of overall survival in colorectal cancer patients according to MSI status. Whereas the MSI-L tumors had poorer survival rate compared with MSI-H or MSS tumors, this result did not reach a significant rate, Log Rank p = 0.426.
Figure 2: Kaplan-Meier curves of overall survival of patients according to MSI status stratified based on TNM stage. (a) Stage II colorectal cancer. Patients with MSI-L tumors showed significantly poorer survival compared with patients who had MSI-H or MSS tumors, Log Rank $p = 0.048$. (b) Stage III/IV colorectal cancer. There is no significant association between survival of patients in advanced stages with MSI status, Log Rank $p = 0.430$.

Figure 3: Kaplan-Meier curves of overall survival of patients according to MSI status stratified based on tumor location. (a) Colon. Patients with low MSI colon cancer showed significantly poorer survival compared with patients who had MSI-H or MSS tumors, Log Rank $p = 0.028$. (b) Rectum. Patients with MSI-H rectal cancer showed poorer survival compared with patients who had MSI-L or MSS tumors, but this finding was not statically significant, Log Rank $p = 0.180$. 
young population in Iran [6, 25]. In the present study we identified 35 MSI-H (22%), 21 MSI-L (13%), and 102 MSS (64%) tumors. MSI-H tumors were predominantly located in the colon than rectum (p = 0.03) and were associated with poorer differentiation (p = 0.003) and tumor, lymph nodes, and metastasis (TNM) stage II/III of tumors (p = 0.02) while MSI-L tumors were more frequent in patients aged younger than 50 years when diagnosed with colorectal cancer. The incidence of MSI observed in 158 colorectal cancer patients in the present study was similar to some previous reports from Iran [20–23], but it was also higher than other reports from other ethnic groups (5–20%) [15–17]. Ashktorab et al. documented a high incidence of MSI (45%) in CRC patients from African Americans population [31]. The incidence of MSI-L reported in this study was higher than another study in Iran [23]. In this study we used 5 mononucleotide markers to evaluate MSI status. Probably different sample sizes and different threshold markers were applied to assign MSI in each previous study, indicating this variety.

In present study CRC patients with stage II MSI-L showed significantly poorer survival compared with patients who had MSI-H or MSS tumors (p = 0.04). This indicates that MSI-L was clearly a marker of poorer prognosis in stage II colorectal cancers. Our results documented distinct clinicopathologic characteristics of MSI-H, MSI-L, and MSS colorectal cancers. In line with other reports, most of the tumors in MSI-H were located in colon, poorly differentiated and frequent in stage III. High incidence of MSI-H in proximal located tumors in the colon was reported in many papers [32, 33]. However, Brim et al. have documented higher frequency of MSI-H tumors in distal colon in Omani patients [34]. The high incidence of MSI-H (24/35, 68.6%) was presented in male gender and there was statistically significant relationship between MSI status and gender (p = 0.01). In CRC patients with stage II, MSI-L cases showed significantly poorer survival compared with patients who had MSI-H or MSS tumors (p = 0.04). In contrast to several papers showing MSI is more common in women than in men [16, 17, 35]; we found a significant association between MSI status and male gender. The high prevalence of MSI-H in male was reported previously, but they did not find any significant association [15, 20]. The prevalence of MSI varied with tumor stage and was highest in stage III. This observation is in contrast to several other studies that showed the highest frequency of MSI in stage II [15–17, 20]. Similar to our finding, many other studies showed that the presence of distant metastases at the time of diagnosis (stage IV) is rare in the MSI subgroup of CRC [15, 20]. In addition, a relatively high frequency of patients diagnosed in age less than 50 was noted; we identified MSI-L tumors predominantly in this group age. The frequency rate of MSI-L in patients with age less than 40 was reported in a previous study in Iran [23], suggesting that this genetic pathway may play an important role in CRC development in Iranian patients between 40 and 50 years old. It has been reported that MSI-H colorectal tumors differ from MSI-L or MSS tumors in several pathological features [36–38] and MSI-L differ from MSS tumors, but the biological background of this feature is unknown [19, 39–43]. It was shown that MLH1 and MSH2 genes do not seem to be contributed to etiology of MSI-L [38]. Studies which indicated the K-ras mutations, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, loss of MGMT gene expression, germline mutation of hMSH6, and a low level of allele loss near APC are associated with the MSI-L phenotype [19, 39–43]. Whereas several studies and two current meta-analyses suggested better prognosis and outcome for patients with MSI-H tumors [44–47], other studies could not confirm these findings [48, 49]. In line with the latter studies we observed no significant difference in overall survival between patients with MSS, MSI-L, and MSI-H tumors. In many prognostic studies, the MSI-L phenotype has not been considered as a separate category; this might be due to a lack of clear single marker for identification of this group of tumors. Our study has shown that MSI-L is associated with poorer survival in colorectal patients with stage II tumors. Many papers suggested that MSI status influences the prognosis of CRC only in specific stages [16, 19, 33, 35, 45]. Two recent studies documented poor prognosis of MSI-L in stage III colon cancer [19, 50]. Kohonen-Corish et al. showed that MSI-L characterizes a distinct subgroup of stage III colon cancer patients including the MSI-L subset of proximal colon cancer who have a poorer clinical outcome [19]. Nevertheless, there is now clear evidence that MSI-L tumors are a discrete molecular group on basis of gene expression data [41]. Together, these data suggest that MSI-L cancer may arise from a distinct carcinogenic pathway as compared to MSS and MSI-H CRC [51]. Other studies suggest that MSI-L and MSS have a common molecular background [52]. Though the biological basis of the good prognosis of patients with MSI-H is somewhat determined, the poor prognosis effect of MSI-L in colon cancer is unknown. It has been reported that the high mutational load in MSI-H tumors elicited a robust host immune response [53]. MSI-L and MSS have a high frequency of mutation of the p53 suppressor gene, explaining aggressive biological characteristics [37, 54]. Few studies have evaluated the effect of MSI status on rectal cancer survival [44, 55]. We assessed MSI status in relation to survival of individuals diagnosed with primary rectal cancer and primary colon cancer. We found poorer prognosis for MSI-L patients who had colon tumors and also poorer prognosis for MSI-H patients with rectum tumors, though this latter finding was not statically significant.

5. Conclusion

In conclusion, this is the first study in Iran to demonstrate the prognostic role of MSI in CRC patients. It seems that the clinical prognostic role of MSI status is dependent on stage and location of the tumor. Further studies with larger sample sizes are required to assess more precisely the impact of MSI-L on clinical outcome.

Competing Interests

All authors declared no conflict of interests.
Acknowledgments

This paper resulted from Ph.D. thesis of Ehsan Nazemalhosseini Mojarrad, student at Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors thank Dr. Hamid Mohaghegh for his valuable advice and Miss Shirin Qafarnejad, Miss Marjan Ebrahimi, and Elmira Khalili for data gathering and technical assistance.

References

[1] K. Soreide, E. A. M. Janssen, H. S ö l i a d , H. K ö r n e r , and J. P. A. Baak, "Microsatellite instability in colorectal cancer," British Journal of Surgery, vol. 93, no. 4, pp. 395–406, 2006.

[2] S. V. Hosseini, A. Izadpanah, and H. Yarmohammadi, "Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980–2000," ANZ Journal of Surgery, vol. 74, no. 7, pp. 547–549, 2004.

[3] A. Rezaianzadeh, A. R. Safarpour, M. Marzban, and A. Mohaghegh, "A systematic review over the incidence of colorectal cancer in Iran," Annals of Colorectal Research, vol. 3, no. 1, Article ID e25724, 2015.

[4] F. Hajmanoochehri, S. Asefzadeh, A. M. Kazemifar, and M. Etehad, "Clinicopathological features of colon adenocarcinoma in Qazvin, Iran: a 16 year study," Asian Pacific Journal of Cancer Prevention, vol. 15, no. 2, pp. 951–955, 2014.

[5] S. Kolahdoozan, A. Sadjadi, A. R. Radmard, and H. Khademi, "Five common cancers in Iran," Archives of Iranian Medicine, vol. 13, no. 2, pp. 143–146, 2010.

[6] R. Malekzadeh, F. Bichehrari, M. Mahdavnia, and R. Ansari, "Epidemiology and molecular genetics of colorectal cancer in Iran: a review," Archives of Iranian Medicine, vol. 12, no. 2, pp. 161–169, 2009.

[7] R. Mahmodlou, P. Mohammadi, and N. Sephehrvand, "Colorectal cancer in northwestern Iran," ISRN Gastroenterology, vol. 2012, Article ID 968560, 4 pages, 2012.

[8] M. R. Rouholahi, M. A. Mohagheghi, N. Mohammadrezaei et al., "Situation analysis of the national comprehensive cancer control program (2013) in the I. R. Of Iran; assessment and recommendations based on the IAEA imPACT mission," Archives of Iranian Medicine, vol. 17, no. 4, pp. 221–231, 2014.

[9] R. Dolatkhah, M. H. Somi, M. J. Bonyadi, I. Asvadi Kermani, F. Farassati, and S. Dastgiri, "Colorectal cancer in Iran: molecular epidemiology and screening strategies," Journal of Cancer Epidemiology, vol. 2015, Article ID 643020, 10 pages, 2015.

[10] M. Pansci, A. Remo, and V. Colantuoni, "Genetic and epigenetic events generate multiple pathways in colorectal cancer progression," Pathology Research International, vol. 2012, Article ID 509348, 11 pages, 2012.

[11] E. Vilar and S. B. Gruber, "Microsatellite instability in colorectal cancer: the stable evidence," Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 153–162, 2010.

[12] D. A. Lawes, S. Sen Gupta, and P. B. Boulos, "The clinical importance and prognostic implications of microsatellite instability in sporadic cancer," European Journal of Surgical Oncology, vol. 29, no. 3, pp. 201–212, 2003.

[13] C. Chapusot, L. Martin, P. L. Puig et al., "What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462 colorectal cancers," American Journal of Surgical Pathology, vol. 28, no. 12, pp. 1553–1559, 2004.

[14] K. Imai and H. Yamamoto, "Carcinogenesis and microsatellite instability: the interrelationship between genetics and epiphenotypes," Carcinogenesis, vol. 29, no. 4, pp. 673–680, 2008.

[15] S. B. Lim, S. Y. Jeong, M. R. Lee et al., "Prognostic significance of microsatellite instability in sporadic colorectal cancer," International Journal of Colorectal Disease, vol. 19, no. 6, pp. 533–537, 2004.

[16] P. Benatti, R. Gafa, D. Barana et al., "Microsatellite instability and colorectal cancer prognosis," Clinical Cancer Research, vol. 11, pp. 8332–8340, 2005.

[17] C. Lamberti, S. Lundin, M. Bogdanow et al., "Microsatellite instability did not predict individual survival of selected patients with colorectal cancer," International Journal of Colorectal Disease, vol. 22, no. 2, pp. 145–152, 2007.

[18] I. Storojeva, J. Boulay, K. Heinimann et al., "Prognostic and predictive relevance of microsatellite instability in colorectal cancer," Oncology Reports, vol. 14, no. 1, pp. 241–249, 2005.

[19] M. R. J. Kohonen-Corish, J. J. Daniel, C. Chan et al., "Low microsatellite instability is associated with poor prognosis in stage C colon cancer," Journal of Clinical Oncology, vol. 23, no. 10, pp. 2318–2324, 2005.

[20] S. Salahshor, U. Kressner, H. Fischer et al., "Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor," British Journal of Cancer, vol. 81, no. 2, pp. 190–193, 1999.

[21] M. Faghani, S. Fakhrieh Asl, F. Mansour-Ghanaei et al., "The correlation between microsatellite instability and the features of sporadic colorectal cancer in the north part of Iran," Gastroenterology Research and Practice, vol. 2012, Article ID 756263, 6 pages, 2012.

[22] A. I. Shemirani, M. M. Haghhighi, S. M. Zadeh et al., "Simplified MSI marker panel for diagnosis of colorectal cancer," Asian Pacific Journal of Cancer Prevention, vol. 12, no. 8, pp. 2101–2104, 2011.

[23] S. Moghbeli, O. Moaven, E. Dadkhah et al., "High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran," Genetics and Molecular Research, vol. 10, no. 4, pp. 3520–3529, 2011.

[24] A. Goel, T. Nagasaka, R. Hamelin, and C. R. Boland, "An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers," PLoS ONE, vol. 5, no. 2, Article ID e9393, 2010.

[25] R. Ansari, M. Mahdavnia, A. Sadjadi et al., "Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry," Cancer Letters, vol. 240, no. 1, pp. 143–147, 2006.

[26] S. M. Mousavi, M. M. Gouya, R. Ramazani, M. Davanlou, N. Hajsadeghi, and Z. Seddighi, "Cancer incidence and mortality in Iran," Annals of Oncology, vol. 20, no. 3, pp. 556–563, 2009.

[27] M. S. Fazeli, M. G. Adel, and A. H. Lebaschi, "Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran university," Diseases of the Colon and Rectum, vol. 50, no. 7, pp. 990–995, 2007.

[28] S. Iravani, E. Nazemalhosseini-Mojarrad, S. M. H. Kashfi, and P. Azimzadeh, "Screening of colorectal diseases among individuals without family history in a private hospital, Tehran, Iran"
Journal of Oncology 9

from 2011 to 2013,” Translational Gastrointestinal Cancer, vol. 3, no. 4, pp. 165–168, 2014.

[30] S. M. Khashif, F. Behboudi Farahbaksh, M. Golmohammadi, E. Nazemalhosseini Mojarad, P. Azimzadeh, and H. Asadzadeh Aghdaie, “Frameshift mutations (deletion at Codon 1309 and Codon 8-9) in the APC gene in Iranian FAP patients: a case series and review of the literature,” International Journal of Molecular and Cellular Medicine, vol. 3, no. 3, pp. 196–202, 2014.

[31] H. Ashktorab, D. T. Smoot, J. M. Carethers et al., “High incidence of microsatellite instability in colorectal cancer from African Americans,” Clinical Cancer Research, vol. 9, no. 3, pp. 1112–1117, 2003.

[32] S. N. Thibodeau, G. Bren, and D. Schaid, “Microsatellite instability in cancer of the proximal colon,” Science, vol. 260, no. 5109, pp. 816–819, 1993.

[33] C. Wang, M. van Rijnsoever, F. Grieu et al., “Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer,” Oncology, vol. 64, no. 3, pp. 259–265, 2003.

[34] H. Brim, P. Mokarram, F. Naghibalhosseaini et al., “Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study,” Molecular Cancer, vol. 7, article 68, 2008.

[35] M. A. Merok, T. Ahlquist, E. C. Reyrvik et al., “Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive norwegian series,” Annals of Oncology, vol. 24, no. 5, pp. 1274–1282, 2013.

[36] R. Ward, A. Meagher, I. Tomlinson et al., “Microsatellite instability and the clinicopathological features of sporadic colorectal cancer,” Gut, vol. 48, no. 6, pp. 821–829, 2001.

[37] S. Mori, Y. Ogata, and K. Shirouzu, “Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis,” International Journal of Clinical Oncology, vol. 9, no. 4, pp. 322–329, 2004.

[38] G. Lanza, R. Gafà, I. Maestri, A. Santini, M. Matteuzzi, and L. Cavazzini, "Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability," Modern Pathology, vol. 15, no. 7, pp. 741–749, 2002.

[39] T. M. Pawlik, C. P. Raut, and M. A. Rodriguez-Bigas, "Colorectal carcinogenesis: MSI-H versus MSI-L," Disease Markers, vol. 20, no. 4-5, pp. 199–206, 2004.

[40] S. Halford, P. Sasiemi, A. Rowan et al., "Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait," Cancer Research, vol. 62, no. 1, pp. 57–57, 2002.

[41] Y. Mori, F. M. Selaru, F. Sato et al., “The impact of microsatellite instability on the molecular phenotype of colorectal tumors,” Cancer Research, vol. 63, no. 15, pp. 4577–4582, 2003.

[42] I. Tomlinson, S. Halford, L. Aaltonen, N. Hawkins, and R. Ward, “Does MSI-low exist?,” The Journal of Pathology, vol. 197, no. 1, pp. 6–13, 2002.

[43] J. R. Jass, I. Tomlinson, S. Halford, L. Aaltonen, N. Hawkins, and R. Ward, “Re: Tomlinson et al. Does MSI-low exist? J Pathol 2002; 197: 6–13 (multiple letters),” Journal of Pathology, vol. 199, no. 2, pp. 267–270, 2003.

[44] S. P. Hong, B. S. Min, T. I. Kim et al., “The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer,” European Journal of Cancer, vol. 48, no. 8, pp. 1235–1243, 2012.

[45] M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton et al., "Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803," Journal of Clinical Oncology, vol. 27, no. 11, pp. 1814–1821, 2009.

[46] S. Popat, R. Hubner, and R. S. Houlston, “Systematic review of microsatellite instability and colorectal cancer prognosis,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 609–618, 2005.

[47] G. Des Guet, O. Schischmanoff, P. Nicolas, G. Perret, J. Morere, and B. Uzzan, “Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis,” European Journal of Cancer, vol. 45, no. 10, pp. 1890–1896, 2009.

[48] W. Meng, X. Sun, C. Tian et al., “Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients,” Oncology, vol. 72, no. 1-2, pp. 82–88, 2007.

[49] C. Du, J. Zhao, W. Xue, F. Dou, and J. Gu, “Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy,” Histopathology, vol. 62, no. 5, pp. 723–730, 2013.

[50] C. M. Wright, O. F. Dent, R. C. Newland et al., “Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma,” Gut, vol. 54, no. 1, pp. 103–108, 2005.

[51] V. L. J. Whitehall, M. D. Walsh, J. Young, B. A. Leggett, and J. R. Jass, “Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability,” Cancer Research, vol. 61, no. 3, pp. 827–830, 2001.

[52] P. Laiho, V. Launonen, P. Lahermo et al., “Low-level microsatellite instability in most colorectal carcinomas,” Cancer Research, vol. 62, no. 4, pp. 1166–1170, 2002.

[53] M. Guidoboni, R. Gafà, A. Viel et al., “Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis,” American Journal of Pathology, vol. 159, no. 1, pp. 297–304, 2001.

[54] A. Morán, P. Iniesta, C. De Juan et al., “Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite colon cancer patients with a favorable prognosis,” Cancer Research, vol. 61, no. 1, pp. 36–40, 2001.

[55] W. S. Samowitz, K. Curtin, R. K. Wolff, S. R. Tripp, B. I. Caan, and M. L. Slattery, “Microsatellite instability and survival in rectal cancer,” Cancer Causes and Control, vol. 20, no. 9, pp. 1763–1768, 2009.